Megan Devine, MD
Pulmonary Disease · Tyler, TXNPI 1255541108
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Genentech USA, Inc. at 42.1% of the total.
Across 259 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- GSK$1K
- Boston Scientific$854
- Boehringer Ingelheim$432
- Sanofi$290
- Insmed, Inc.$264
- plus $2K from 31 others
Across 112 payments — averaging $2678.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$124K
- Sanofi US Services Inc.$59K
- Mannkind Corporation$36K
- Verona Pharma, Inc.$30K
- AstraZeneca$20K
- Boehringer Ingelheim$16K
- plus $13K from 3 others
What the payments were for
- Speaking & faculty fees$3,40039%
- Food & beverage$5,19259%
- Education$2343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 12 | $3,719 |
| GSK | 85 | $1,037 |
| Boston Scientific | 17 | $854 |
| Boehringer Ingelheim | 17 | $432 |
| Sanofi | 11 | $290 |
| Insmed, Inc. | 10 | $264 |
| Actelion Pharmaceuticals US, Inc. | 8 | $244 |
| AstraZeneca | 15 | $231 |
| United Therapeutics Corporation | 7 | $162 |
| AbbVie | 7 | $153 |
| Vertex | 7 | $150 |
| Ambu Inc. | 2 | $147 |
| Mylan Specialty L.p. | 8 | $138 |
| Vivus LLC | 4 | $79 |
| Innovation Technologies Inc | 1 | $78 |
| Regeneron Healthcare Solutions, Inc. | 4 | $76 |
| ANI Pharmaceuticals, Inc. | 3 | $74 |
| Aimmune Therapeutics, Inc. | 3 | $69 |
| Inogen, Inc. | 8 | $59 |
| Grifols USA, LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Philips North America LLC | 3 | $45 |
| Electromed, Inc. | 3 | $41 |
| Baxter Healthcare | 2 | $40 |
| Optinose US, Inc. | 2 | $40 |
| Harmony Biosciences LLC | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Grifols Shared Services North America, Inc. | 1 | $35 |
| Merck | 2 | $33 |
| Integra Lifesciences Corporation | 1 | $31 |
| Viatris Specialty LLC | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Hospira, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,826 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 51 | $1,608,479 |
| OpsumitMacitentan | 58 | $727,524 |
| OfevNintedanib Esylate | 31 | $402,501 |
| UptraviSelexipag | 20 | $353,219 |
| AdempasRiociguat | 13 | $183,272 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 15 | $167,379 |
| EsbrietPirfenidone | 13 | $138,341 |
| Ambrisentan | 22 | $98,120 |
| NucalaMepolizumab | 22 | $81,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $60,863 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $24,995 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $18,733 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $16,982 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $14,811 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $150 | $1,608,47951 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $244 | $1,080,74478 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $432 | $430,19064 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,037 | $191,128227 claims |
| Grifols USA, LLCProlastin C | $57 | $167,37915 claims |
| Genentech USA, Inc.Esbriet | $3,719 | $138,34113 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $231 | $25,41360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Tyler
- Ketan PatelTyler$208K
- Pamela McShaneTyler$184K
- Julie PhilleyTyler$68K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.